CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 330 enrolled
Drug / intervention
Tranexamic Acid +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02578901
NCT02578901Phase 3Completed
CompareCT.gov

American Trial Using Tranexamic Acid in Thrombocytopenia (A-TREAT)

University of Washington·interventional·Posted Oct 19, 2015·Updated Mar 24, 2021

In Brief

A Phase 3 clinical trial evaluating Tranexamic Acid and Placebo for Thrombocytopenia. Completed, enrolled 330 participants across 3 sites.

Detailed Summary

The purpose of this study is to evaluate the usefulness of antifibrinolytic therapy with tranexamic acid (TXA) in preventing bleeding in patients who are thrombocytopenic due to primary bone marrow disorders or chemotherapy, immunotherapy and/or radiation therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThrombocytopenia
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 19, 2015
Enrollment StartJun 1, 2016
Primary CompletionMar 1, 2020
Study CompletionJun 11, 2020
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 10.7 years ago

Interventions

Tranexamic Aciddrug

Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, TXA 1.0 gram will be administered. When given PO, TXA 1.3 grams will be administered

Placebodrug

Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, Normal Saline will be administered. When given PO, placebo pills will be administered